Pfizer offers EU concessions for Hospira deal OK; Glaxo teams up with Crick on HIV, cancer;

@FiercePharma: FDA cracks down on Vegas firm selling unapproved kidney drug for dogs and cats. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Emcure plant in Hinjwadi added to growing list of Indian facilities banned by FDA. More | Follow @EricPFierce

@CarlyHFierce: UPDATED with quote from $HZNP CEO Walbert: Depomed swallows poison pill to keep hostile Horizon at bay. Story | Follow @CarlyHFierce

> Pfizer ($PFE) offered concessions to win EU regulatory approval for its $15 billion takeover of U.S.-based Hospira ($HSP); details of Pfizer's proposal weren't disclosed. Report

> GlaxoSmithKline ($GSK) became the first drugmaker to hook up with England's new open innovation-focused Crick Institute, in a partnership focused on HIV, malaria and cancer. Release

> Greece banned exports of 25 drugs after finding abuses in re-exporting imported medicines, amid worries about shortages in the cash-strapped country. Report

> Bayer HealthCare won European approval for its imaging agent Gadovist (gadobutrol) for use in children under 2 years of age. Release

Medical Device News

@FierceMedDev: ICYMI: Xagenic reels in $15M for point-of-care testing system. FierceDiagnostics story | Follow @FierceMedDev\

@VarunSaxena2: ICYMI yesterday: India moving closer to implementing price controls on medical devices. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Otsuka, Lundbeck bag blockbuster FDA approval for long-acting antipsychotic Rexulti. Story | Follow @EmilyWFierce

> Valeant to buy contact lens maker Unilens for $28M. Story

> Gentag, Mayo Clinic and others form JV to develop cheap, painless smartphone-based diabetes tech. Article

Biotech News

@FierceBiotech: Biopharma's 10 highest-paid heads of R&D. Feature | Follow @FierceBiotech

@JohnCFierce: BRIEF: Celgene backing Soon-Shiong's cancer biotech IPO, now dubbed NantKwest. Item | Follow @JohnCFierce

@DamianFierce: $SHPG's Ornskov has A+ dramaturgy. Was it "Can't Get You Outta My Head," @jonathanrockoff? More | Follow @DamianFierce

> Sarepta wants to 'own DMD' in rare disease race with BioMarin. Story

> GlaxoSmithKline joins the U.K.'s new Crick Institute for some open R&D. Article

> Biotech legend Lee Hood gambles $36M on a plan to revolutionize healthcare. Report

Pharma Manufacturing News

> Novartis' Sandoz puts India plant on chopping block. News

> Takeda recalls thousands of Contrave bottles even as it fights over canceled trial. Report

> WuXi selling chunk of SynTheAll to raise $80M for plant expansion. Story

> Catalent says it has resolved issues FDA noted at North Carolina site. Item

> Fresenius Kabi, Calea fined $844,600 for lapses tied to patient death. Article

Pharma Asia News

> Almac's launch of Singapore APAC HQ also eyes regional growth of small biotechs. Article

> Fujifilm Chief Komori discusses R&D, earnings outlook, but not duodenoscopes. Story

> China's aim to halt malaria gets a thumbs up from WHO as global effort grows. Report

> Private placement of 6% in WuXi's SynTheAll unit raises $80M to fund manufacturing boost. More

Drug Delivery News

> Researcher says more work needed on use of nanocarriers in fight against stroke, heart disease. Report

> Eczema cream posts strong results in PhIII trial. Item

> Parisian MIT spinoff pulls in €2M to fund CRISPR delivery work. News

> Valeant to commercialize and manufacture EyeGate's eye drug delivery device. Story

> Neos files for $60M IPO with easy-to-swallow tablets for ADHD. Article

And Finally… The Obama administration has dragged its feet on FDA funding and implementation for a landmark food safety law passed in 2010, Politico reports. Story

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.